Efficacy and Safety of Autologous Cytokine-Induced Killer (CIK) Cellular Immunotherapy Combined with Chemotherapy in Non-Small-Cell Carcinoma (NSCLC): A Meta-analysis

To investigate the efficacy and safety of autologous Cytokine-induced killer (CIK) cellular immunotherapy combined with chemotherapy for non-small-cell carcinoma (NSCLC).

The literature related to the efficacy and safety of autologous CIK cellular immunotherapy combined with chemotherapy in NSCLC were collected. The Chinese literature databases were collected from CNKI, Wanfang and Weipu, and the English literature were retrieved from Cochrane Library and PubMed. All literature were retrieved until the year of 2022, and evaluated by its method quality and analyzed by RevMan5.3 software.

A Meta-analysis on the 11 included literature showed that the treatment efficacy and disease control rate (DCR) of patients in the observation group were significantly higher than those in the control group (P＜0.05), and significantly increased the levels of CD3+, CD4+, CD4+/CD8+ indexes than the control group (P＜0.05), and the incidence of bone marrow suppression, liver injury and gastrointestinal symptoms were significantly lower than those of the control group (P＜0.05).

Compared with single chemotherapy, CIK combined with chemotherapy in the treatment of patients with NSCLC can improve the efficacy of treatment and DCR, significantly improve their immune function, reduce the incidence of adverse reactions, and is beneficial to the recovery of prognosis.